Longitude Capital Partners III, LLC

Insider Reports History

Entity
Company
Location
800 El Camino, Suite 220, Menlo Park, CA
Signature
Longitude Venture Partners III, L.P.; By /s/ Patrick G. Enright, Managing Member of the general partner
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Longitude Capital Partners III, LLC:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Talaris Therapeutics, Inc. 10%+ Owner Common Stock 3.22M $54.7M $16.99 May 11, 2021 By Longitude Venture Partners III, L.P.
Inozyme Pharma, Inc. 10%+ Owner Common Stock 4.17M $14.9M $3.57 Apr 19, 2022 By Longitude Venture Partners III, L.P.
Sierra Oncology, Inc. 10%+ Owner Common Stock 8.02K $441K $55.00 Apr 27, 2022 Indirect
Talaris Therapeutics, Inc. 10%+ Owner Series A-1 Preferred Stock 0 May 11, 2021 By Longitude Venture Partners III, L.P.
Talaris Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 0 May 11, 2021 By Longitude Venture Partners III, L.P.
Talaris Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 0 May 11, 2021 By Longitude Venture Partners III, L.P.

Insider Reports Filed by Longitude Capital Partners III, LLC

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SRRA Sierra Oncology, Inc. Apr 27, 2022 8 $0 4 Apr 29, 2022 10%+ Owner
INZY Inozyme Pharma, Inc. Apr 19, 2022 1 $5M 4 Apr 21, 2022 10%+ Owner
SRRA Sierra Oncology, Inc. Jan 31, 2022 1 $4.73M 4 Feb 2, 2022 10%+ Owner
SRRA Sierra Oncology, Inc. Jan 25, 2022 2 -$13.1M 4 Jan 27, 2022 10%+ Owner
TALS Talaris Therapeutics, Inc. May 11, 2021 5 $4M 4 May 11, 2021 10%+ Owner